Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 3, 2019

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2028

Conditions
Renal Cell CarcinomaMetastatic Renal Cell CarcinomaKidney CancerRenal CarcinomaKidney Cancer Metastatic
Interventions
DRUG

Olaparib

Olaparib is a crystalline solid, is non-chiral and shows pH-independent solubility of approximately 0.1 mg/mL across the physiological range. Olaparib is presented for oral administration as a green, film-coated tablet containing 25 mg, 100 mg or 150 mg of drug substance. The 100 mg strength is also available as a yellow, film-coated tablet. The 25 mg, 100 mg and 150 mg strengths of olaparib tablets are composed of the same constituents. The tablet cores comprise: olaparib, copovidone, colloidal silicon dioxide, mannitol and sodium stearyl fumarate. The composition of the green tablet film coating is: hydroxypropyl methylcellulose (hypromellose), macrogol 400 (polyethylene glycol 400), titanium dioxide, iron oxide yellow and iron oxide black. The yellow tablet film coating only differs from the green film coating with the omission of iron oxide black.

Trial Locations (1)

21228

RECRUITING

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER